Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer

PHASE2

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped The study was closed early due to safety concerns and an unfavorable benefit-risk balance. Unexpected high neutropenia rates required a costly sub-study, which was not feasible, forcing the sponsor to terminate the trial prematurely.

Conditions

HER2-positive Metastatic Breast Cancer
Locally Advanced HER2 Positive Breast Carcinoma

Interventions

DRUG: Tucatinib
DRUG: Trastuzumab
DRUG: Vinorelbine

Sponsor

Spanish Breast Cancer Research Group

Collaborators

[object Object]